CyBorD-DARA in Newly Diagnosed Transplant-Eligible Multiple Myeloma: Results from the 16-BCNI-001/CTRIAL-IE 16-02 Study Show High Rates of MRD Negativity at End of Treatment
| Autor: | Swan, D., Henderson, R., McEllistrim, C., Naicker, S.D., Quinn, J., Cahill, M.R., Mykytiv, V., Lenihan, E., Mulvaney, E., Nolan, M., Parker, I., Natoni, A., Lynch, K., Ryan, A.E., Szegezdi, E., Krawczyk, J., Murphy, P., O'Dwyer, M. |
|---|---|
| Zdroj: | In Clinical Lymphoma, Myeloma and Leukemia November 2022 22(11):847-852 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect